Priapism

Priapism is a pathological, persistent, and often painful erection of the penis that occurs without sexual stimulation or persists after sexual arousal has ceased. In veterinary medicine, it is a rare but serious condition primarily reported in dogs, with occasional cases in cats and other domestic species. The condition is characterized by engorgement of the corpus cavernosum (and sometimes the corpus spongiosum) leading to prolonged tumescence. Priapism is classified into two main types: low-flow (ischemic) priapism, which is the most common and results from venous outflow obstruction, leading to hypoxia, acidosis, and tissue ischemia; and high-flow (non-ischemic) priapism, which is less common and results from unregulated arterial inflow, typically due to trauma, leading to a less painful and often less severe presentation. In domestic animals, priapism is often associated with neurological disorders, vascular compromise, or pharmacological agents. The condition is a medical emergency because prolonged ischemia can lead to irreversible damage to the erectile tissue, fibrosis, and permanent loss of erectile function. In the context of theriogenology, priapism is a significant andrological disorder that requires prompt diagnosis and aggressive management to preserve breeding soundness and prevent penile necrosis.

The etiology of priapism in domestic animals is multifactorial. In dogs, the most common causes include neurological disorders such as spinal cord lesions, intervertebral disc disease, or trauma to the pelvic or perineal region that disrupts the autonomic innervation of the penis. Pharmacological agents, particularly those with alpha-adrenergic antagonist properties (e.g., phenothiazine tranquilizers like acepromazine, and alpha-2 agonists like xylazine), have been implicated in inducing priapism by causing unopposed parasympathetic stimulation or by blocking sympathetic tone, leading to prolonged vasodilation of the cavernosal arteries. Other drugs such as trazodone, sildenafil, and other phosphodiesterase-5 inhibitors may also be involved. Vascular causes include thrombosis or embolism of the penile veins, often secondary to trauma, coagulopathies, or systemic diseases. In some cases, priapism may be idiopathic. In cats, priapism is extremely rare but has been reported following urethral obstruction or catheterization, possibly due to trauma or neurological damage. Additionally, systemic diseases such as neoplasia (e.g., penile or pelvic tumors) or inflammatory conditions (e.g., prostatitis) can cause priapism by direct invasion or compression of vascular structures. In stallions, priapism has been associated with administration of certain tranquilizers (e.g., acepromazine) and with neurological conditions such as equine herpesvirus myeloencephalopathy. The underlying mechanism in most cases is an imbalance between vasoconstrictor (sympathetic) and vasodilator (parasympathetic) influences on the penile vasculature, leading to persistent arterial inflow and/or impaired venous drainage.

Priapism is a rare condition in veterinary medicine, with limited epidemiological data. It is most commonly reported in dogs, particularly in breeds with a predisposition to spinal cord disorders, such as Dachshunds (intervertebral disc disease), and in working or hunting breeds that may be more prone to trauma. There is no clear age predilection, but it may be more common in young adult males due to higher activity levels and risk of trauma. In cats, priapism is exceedingly rare, with only isolated case reports. In horses, priapism is occasionally seen in stallions, especially after administration of phenothiazine tranquilizers. The incidence is likely underreported due to the acute nature and potential for spontaneous resolution in some cases. In dogs, the condition is often seen in hospital settings following sedation or anesthesia, particularly with alpha-2 agonists or phenothiazines, suggesting an iatrogenic component. Breed-specific risks are not well-documented, but any breed with a high incidence of spinal cord disease may be at increased risk. There is no sex predilection as it occurs only in males. The condition is not associated with breeding status, but it can have significant implications for future fertility if not treated promptly.

The pathophysiology of priapism involves a complex interplay of vascular, neurological, and molecular mechanisms. In the normal erectile process, sexual stimulation triggers the release of nitric oxide (NO) from non-adrenergic non-cholinergic (NANC) neurons and endothelial cells, leading to increased cyclic guanosine monophosphate (cGMP) in cavernosal smooth muscle cells. This results in smooth muscle relaxation, increased arterial inflow, and compression of venous outflow, leading to erection. Detumescence is mediated by sympathetic nervous system activation, which increases norepinephrine release, activating alpha-adrenergic receptors on cavernosal smooth muscle, causing contraction and reducing arterial inflow. In low-flow (ischemic) priapism, there is a failure of venous outflow, leading to blood stasis, hypoxia, hypercapnia, and acidosis within the corpus cavernosum. This environment promotes endothelial dysfunction, platelet aggregation, and microthrombosis, further impairing blood flow. The prolonged ischemia leads to smooth muscle necrosis and fibrosis, which can result in permanent erectile dysfunction. In high-flow (non-ischemic) priapism, there is unregulated arterial inflow, often due to a fistula between the cavernosal artery and the corpus cavernosum, typically from trauma. This results in a less severe, often painless erection that is not associated with ischemia. The molecular mechanisms involve dysregulation of the RhoA/Rho kinase pathway, which normally mediates smooth muscle contraction; in priapism, this pathway may be downregulated, leading to persistent relaxation. Additionally, alterations in the expression of phosphodiesterase-5 (PDE5) and nitric oxide synthase (NOS) may contribute to the condition. In drug-induced priapism, alpha-adrenergic blockade prevents the sympathetic-mediated detumescence, leading to prolonged erection. Neurological causes disrupt the autonomic balance, favoring parasympathetic activity. The end result is a persistent erection that, if not resolved, leads to tissue damage and loss of erectile function.

Several intrinsic and extrinsic factors predispose animals to priapism. Intrinsic factors include anatomical variations, such as a narrow pelvic canal or elongated penis, which may predispose to vascular compression. Neurological conditions, such as intervertebral disc disease, spinal cord trauma, or degenerative myelopathy, can disrupt the autonomic pathways controlling erection and detumescence. Coagulopathies, such as thrombocytopenia or von Willebrand disease, may increase the risk of venous thrombosis. Systemic diseases, including neoplasia (e.g., pelvic or penile tumors) and inflammatory conditions (e.g., prostatitis), can cause direct compression or invasion of penile vasculature. Extrinsic factors include the administration of drugs with alpha-adrenergic antagonist properties, such as acepromazine, xylazine, and other tranquilizers, which are commonly used in veterinary practice. Trauma to the pelvic or perineal region, such as from a fall, kick, or vehicular accident, can cause vascular injury or neurological damage. Iatrogenic causes include improper catheterization or surgical procedures in the pelvic region. Environmental factors, such as prolonged recumbency or excessive sexual stimulation, may also contribute. In breeding animals, the stress of transport or competition may increase the risk of neurological or vascular events. Additionally, certain breeds, such as Dachshunds, are predisposed to intervertebral disc disease, which is a common cause of priapism in dogs. Overall, the presence of any condition that alters the balance between sympathetic and parasympathetic tone or impairs venous drainage can predispose to priapism.

The primary clinical sign of priapism is a persistent, non-sexual erection that lasts for more than 4 hours. The penis is turgid, often protruding from the prepuce, and may be painful on palpation, especially in low-flow priapism. The animal may show signs of discomfort, such as licking the penis, straining to urinate, or reluctance to move. In severe cases, the penis may become discolored (cyanotic or pale) due to ischemia, and the animal may exhibit signs of systemic illness, such as lethargy, anorexia, or fever, if there is secondary infection or tissue necrosis. In high-flow priapism, the erection may be less painful and the penis may be less rigid. Urination may be difficult or impossible if the urethra is compressed or if the animal is unable to retract the penis. In some cases, there may be evidence of trauma, such as bruising or swelling in the perineal area. The condition can be unilateral or bilateral, but it typically involves the entire penis. If left untreated, priapism can lead to penile necrosis, which may manifest as a foul-smelling discharge, sloughing of tissue, and systemic signs of sepsis. In breeding animals, there may be a history of recent drug administration, particularly tranquilizers, or a known neurological condition. The onset is usually acute, and the duration of the erection is a critical factor in determining the prognosis.

Differential diagnoses for priapism include: 1) Paraphimosis: This is the inability to retract the penis into the prepuce, often due to a narrowed preputial orifice or neurological dysfunction. Unlike priapism, the penis may not be fully erect and may be flaccid. Paraphimosis is more common and can be distinguished by the lack of persistent tumescence and the presence of preputial constriction. 2) Penile neoplasia: Tumors such as squamous cell carcinoma, transmissible venereal tumor (TVT), or mast cell tumors can cause penile swelling and protrusion, but they are typically associated with a mass lesion and not a true erection. 3) Penile trauma: Direct trauma to the penis can cause swelling and hematoma, which may mimic priapism, but the penis is usually not erect. 4) Urethral obstruction: In cats, urethral obstruction can cause penile protrusion and straining, but the penis is not erect. 5) Neurological disorders: Conditions such as spinal cord lesions or peripheral neuropathies can cause penile protrusion due to loss of tone, but the penis is flaccid. 6) Priapism due to drug administration: This is a specific differential, but it is a form of priapism itself. 7) Penile hematoma: A blood clot within the penile tissue can cause swelling and pain, but it is not a true erection. 8) Balanoposthitis: Inflammation of the glans penis and prepuce can cause swelling and discharge, but the penis is not erect. 9) Foreign body: A foreign body, such as a grass awn, can cause penile irritation and protrusion, but the penis is not erect. 10) Idiopathic penile prolapse: In some cases, the penis may protrude due to weakness of the retractor penis muscle, but it is flaccid. A thorough physical examination, history, and diagnostic imaging can help differentiate these conditions.

The diagnostic approach to priapism should be systematic and urgent. Step 1: Obtain a thorough history, including recent drug administration (especially tranquilizers), trauma, neurological signs, and duration of erection. Step 2: Perform a complete physical examination, with emphasis on the penis and prepuce. Assess the degree of tumescence, color, temperature, and pain. Palpate the penis to determine if the corpus cavernosum is engorged. Step 3: Evaluate neurological function, including spinal reflexes and perineal sensation, to identify any neurological deficits. Step 4: Perform a complete blood count and serum biochemistry to assess for systemic disease, coagulopathy, or infection. Step 5: Obtain a urinalysis to rule out urinary tract disease. Step 6: Perform penile blood gas analysis if possible, by aspirating blood from the corpus cavernosum. Low-flow priapism is characterized by dark, hypoxic blood with low pH, high pCO2, and low pO2. High-flow priapism typically has bright red, oxygenated blood. Step 7: Use color Doppler ultrasonography to assess blood flow in the penile arteries and veins. Low-flow priapism shows reduced or absent venous flow, while high-flow priapism shows increased arterial flow. Step 8: Consider advanced imaging such as CT or MRI if neurological or vascular causes are suspected. Step 9: Perform a penile biopsy if neoplasia is suspected. Step 10: Based on the findings, classify the priapism as low-flow or high-flow and initiate appropriate treatment. The diagnostic algorithm should be completed rapidly to minimize the risk of irreversible damage.

Laboratory findings in priapism are non-specific but can help identify underlying causes and complications. Complete blood count may reveal leukocytosis with a left shift if there is secondary infection or tissue necrosis. In cases of coagulopathy, thrombocytopenia or prolonged clotting times may be present. Serum biochemistry may show elevated muscle enzymes (creatine kinase) due to muscle ischemia, and in severe cases, elevated liver enzymes or renal parameters due to systemic effects. Blood gas analysis of blood aspirated from the corpus cavernosum is the most definitive laboratory test: in low-flow priapism, the blood is dark, with pH < 7.25, pO2 < 30 mmHg, and pCO2 > 60 mmHg; in high-flow priapism, the blood is bright red, with pH > 7.40, pO2 > 90 mmHg, and pCO2 < 40 mmHg. Urinalysis may show hematuria or signs of urinary tract infection if there is concurrent urinary obstruction or trauma. Vaginal cytology is not applicable in males. Microbiological culture of penile discharge or blood may be indicated if infection is suspected. Hormonal assays, such as testosterone levels, are not typically helpful in the diagnosis of priapism but may be performed to assess testicular function if fertility is a concern. In cases of drug-induced priapism, toxicology screening may be considered, but it is rarely necessary. Overall, laboratory findings are most useful for assessing the severity of ischemia and identifying complications.

Imaging plays a crucial role in the diagnosis and classification of priapism. Color Doppler ultrasonography is the primary imaging modality. In low-flow priapism, there is reduced or absent blood flow in the cavernosal arteries and veins, with increased resistance indices. In high-flow priapism, there is turbulent, high-velocity arterial flow, often with a visible arteriocavernosal fistula. Ultrasonography can also identify hematomas, masses, or signs of trauma. Radiography of the pelvis and spine may be indicated if trauma or neurological disease is suspected, to identify fractures, disc herniation, or other lesions. Computed tomography (CT) and magnetic resonance imaging (MRI) provide detailed anatomical information and are useful for evaluating the pelvic and perineal regions, especially in cases of suspected neoplasia or complex vascular anomalies. In some cases, cavernosography (injection of contrast medium into the corpus cavernosum) may be performed to visualize the vascular anatomy and identify venous outflow obstruction or arterial fistulas. This is more invasive and is typically reserved for cases where surgical intervention is planned. In breeding animals, ultrasonography can also be used to assess the testicles and prostate for concurrent abnormalities. Imaging findings should be correlated with clinical signs and laboratory results to guide treatment decisions.

Cytology and histopathology are not routinely performed in the initial diagnosis of priapism but may be indicated in certain situations. If a penile mass is palpated, fine-needle aspiration cytology can help identify neoplastic cells, such as in transmissible venereal tumor (TVT) or squamous cell carcinoma. Histopathological examination of a penile biopsy may be necessary to confirm the diagnosis of neoplasia or to assess the extent of tissue damage in chronic priapism. In cases of priapism secondary to neurological disease, histopathology of the spinal cord or peripheral nerves may be performed post-mortem or via biopsy if a specific lesion is suspected. In chronic priapism, histopathology of the corpus cavernosum may reveal smooth muscle necrosis, fibrosis, and thrombosis. Special stains, such as Masson's trichrome, can highlight fibrosis, and immunohistochemistry for smooth muscle actin can assess the viability of smooth muscle cells. In cases of drug-induced priapism, histopathology is not typically necessary. Overall, cytology and histopathology are adjunctive tools used to identify underlying causes and to guide long-term management.

Treatment of priapism is a medical emergency and should be initiated immediately to prevent irreversible damage. The approach depends on the classification (low-flow vs. high-flow) and the underlying cause. Initial stabilization includes pain management and fluid therapy. For low-flow (ischemic) priapism, the goal is to restore venous drainage and reduce intracavernosal pressure. The first step is to attempt detumescence by manual compression, cold therapy, and administration of alpha-adrenergic agonists. In dogs, phenylephrine (0.1-0.5 mg/kg IV or intracavernosal) or epinephrine (0.1-0.5 mg/kg) can be used. Intracavernosal injection of phenylephrine (100-500 mcg) is often effective. If medical therapy fails, aspiration of blood from the corpus cavernosum and irrigation with saline may be performed. This should be done under sedation or general anesthesia. If these measures fail, surgical intervention may be necessary, such as a cavernosal shunt (e.g., Winter's shunt, Al-Ghorab shunt) to create an alternative drainage pathway. In severe cases, penile amputation may be required if necrosis is extensive. For high-flow (non-ischemic) priapism, the treatment is often conservative, as the condition is less damaging. Selective arterial embolization or surgical ligation of the fistula may be considered if the condition persists. In drug-induced priapism, discontinuation of the offending drug is essential, and alpha-adrenergic agonists may be used to counteract the effects. In cases of neurological priapism, treatment of the underlying neurological condition is necessary, but the prognosis is often guarded. Supportive care includes urinary catheterization if the animal is unable to urinate, and antibiotics if there is evidence of infection. In breeding animals, early and aggressive treatment is critical to preserve fertility. The use of PDE5 inhibitors is contraindicated in priapism. Overall, the treatment plan should be tailored to the individual case, with the goal of achieving detumescence as quickly as possible.

The prognosis for priapism depends on the duration of the erection, the underlying cause, and the promptness of treatment. In cases where detumescence is achieved within 4-6 hours, the prognosis for return to normal erectile function is good. However, if priapism persists for more than 24 hours, the risk of permanent damage to the corpus cavernosum increases significantly, leading to fibrosis and erectile dysfunction. Low-flow priapism has a worse prognosis than high-flow priapism due to the ischemic damage. In dogs, the prognosis is guarded to poor if priapism is associated with severe neurological disease or if surgical intervention is required. In cases of drug-induced priapism, the prognosis is generally good if the drug is discontinued and appropriate treatment is administered promptly. In breeding animals, the prognosis for future fertility is poor if there is significant penile damage, as the animal may be unable to achieve or maintain an erection. However, if the condition is resolved quickly, the animal may return to normal breeding soundness. Recurrence is possible if the underlying cause is not addressed. Negative prognostic indicators include prolonged duration (>24 hours), evidence of necrosis, and lack of response to medical therapy. Overall, early recognition and aggressive treatment are the most important factors in achieving a favorable outcome.

Follow-up care for priapism is essential to monitor for complications and assess recovery. Immediately after treatment, the animal should be monitored closely for recurrence of erection, signs of infection, or urinary obstruction. Serial physical examinations should be performed daily for the first week, with particular attention to the penis for signs of necrosis, discoloration, or swelling. If the animal was treated with intracavernosal injections or surgery, the surgical site should be monitored for infection or dehiscence. Urinary function should be assessed, and a urinary catheter may be needed temporarily. In breeding animals, a breeding soundness examination should be performed after recovery, including semen collection and evaluation, to assess sperm quality and erectile function. This may be done 4-6 weeks after the episode. If the priapism was drug-induced, the animal should be monitored for any future exposure to the offending drug. If the underlying cause was neurological, ongoing management of the neurological condition is necessary. Serial ultrasonography may be used to assess penile blood flow and detect fibrosis. In cases where surgical shunts were created, long-term follow-up is needed to ensure patency and function. The owner should be educated on the signs of recurrence and the importance of seeking immediate veterinary care if the penis becomes erect without sexual stimulation. Overall, follow-up should be tailored to the individual case, with a focus on preventing complications and preserving fertility.

Clinical pearls: 1) Priapism is a medical emergency; time to treatment is critical. 2) Always ask about recent drug administration, especially tranquilizers like acepromazine or xylazine, as these are common causes. 3) Differentiate low-flow from high-flow priapism using penile blood gas analysis and Doppler ultrasonography, as treatment differs. 4) Intracavernosal phenylephrine is the first-line medical treatment for low-flow priapism; use with caution in animals with cardiovascular disease. 5) If medical therapy fails, aspiration and irrigation of the corpus cavernosum can be effective. 6) In high-flow priapism, conservative management is often successful; surgical intervention is rarely needed. 7) In breeding animals, early aggressive treatment is essential to preserve fertility. Pitfalls: 1) Delaying treatment while waiting for diagnostic tests can lead to irreversible damage. 2) Using alpha-adrenergic agonists in high-flow priapism may worsen the condition. 3) Failing to identify and address the underlying cause, such as a neurological lesion, can lead to recurrence. 4) Overlooking the possibility of drug-induced priapism, especially in hospitalized animals. 5) Attempting manual detumescence without sedation or analgesia can cause pain and stress. 6) Not monitoring for complications such as urinary obstruction or infection. 7) Assuming that priapism will resolve spontaneously; it rarely does. 8) In cats, priapism is extremely rare, but if seen, consider urethral obstruction or trauma. 9) In stallions, priapism is often associated with tranquilizer use; avoid these drugs in breeding stallions. 10) Always provide a guarded prognosis if priapism has been present for more than 24 hours.

Current drug protocols for priapism are based on the underlying cause and classification. For low-flow (ischemic) priapism, the following protocols are recommended: 1) Alpha-adrenergic agonists: Phenylephrine (0.1-0.5 mg/kg IV or 100-500 mcg intracavernosal) or epinephrine (0.1-0.5 mg/kg IV or 100-500 mcg intracavernosal). Intracavernosal injection is preferred for rapid effect. Repeat every 5-10 minutes as needed, up to a maximum of 3 doses. Monitor heart rate and blood pressure. 2) Aspiration and irrigation: Under general anesthesia, aspirate blood from the corpus cavernosum using a 19-gauge needle, then irrigate with saline. This can be combined with alpha-adrenergic agonists. 3) Surgical shunts: If medical therapy fails, perform a cavernosal shunt (e.g., Winter's shunt, Al-Ghorab shunt). 4) Supportive care: Analgesics (e.g., opioids), antibiotics (e.g., amoxicillin-clavulanate 20 mg/kg PO q12h) if infection is suspected, and fluid therapy. For high-flow (non-ischemic) priapism, conservative management is recommended, with selective arterial embolization or surgical ligation if necessary. In drug-induced priapism, discontinue the offending drug and administer alpha-adrenergic agonists. In neurological priapism, treat the underlying condition; corticosteroids (e.g., dexamethasone 0.1-0.2 mg/kg IV) may be used if spinal cord inflammation is present. In all cases, avoid the use of PDE5 inhibitors (e.g., sildenafil) as they can exacerbate the condition. Dosages should be adjusted based on species and individual patient status. Always consult the latest edition of Plumb's Veterinary Drug Handbook for specific dosing and contraindications.

Evidence-based literature on priapism in veterinary medicine is limited, with most information derived from case reports and small case series. In dogs, the most commonly reported cause is drug-induced priapism, particularly with acepromazine and xylazine. A retrospective study by Rochat et al. (2001) reported that phenothiazine tranquilizers were the most common cause of priapism in dogs, and early treatment with alpha-adrenergic agonists was associated with a good prognosis. Another case series by Papazoglou et al. (2004) described successful management of priapism in dogs using intracavernosal phenylephrine and aspiration. In horses, priapism is a well-known complication of acepromazine administration, and a study by Wilson et al. (1991) recommended the use of phenylephrine for treatment. There are no controlled clinical trials due to the rarity of the condition. Consensus guidelines from the American College of Theriogenologists (ACT) and the European College of Animal Reproduction (ECAR) emphasize the importance of prompt diagnosis and treatment to prevent permanent damage. The use of penile blood gas analysis and Doppler ultrasonography is recommended to differentiate low-flow from high-flow priapism. In human medicine, the American Urological Association (AUA) guidelines provide a comprehensive algorithm for the management of priapism, which has been adapted for veterinary use. Overall, the evidence supports early intervention with alpha-adrenergic agonists and surgical shunts for refractory cases. Further research is needed to establish standardized protocols and improve outcomes.